Skip to content
Screener

GeneDx Holdings WGS Q1 2025 earnings

Reported April 30, 2025 · Before market open

Revenue$87.1MBeat by $1.8M
EPS$0.28Beat by $0.17
Revenue estimate$85.3M
EPS estimate$0.11

Next report

Oct 27, 2026 (in a month)
Revenue estimate$123.0M
EPS estimate$0.07

Financials

Q1 2025

Income statement

See full
Revenue$87.1M+39.6%
Gross profit$58.5M+56.3%
Operating income-$4.6M+66.7%
Net income-$6.5M+67.7%
EPS (diluted)-$0.23+70.5%

Balance sheet

See full
Cash & equivalents$100.7M+18.9%
Total debt$53.0M-0.2%
Total equity$257.4M+24.2%
Total assets$446.4M+13.2%

Cash flow

See full
Operating cash flow$10.2M+162%
CapEx$6.1M+1,284%
Free cash flow$4.1M+124%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.49B+945%
Enterprise value$2.44B+1,082%
P/S7.5×+6.5×

Profitability

See full
Gross margin65.3%+14.7pp
FCF margin-4%-1.9pp

Returns & leverage

See full
Debt / equity0.2×-0.1×
Current ratio3.2×0.0×

FAQ

When did GeneDx Holdings report Q1 2025 earnings?
GeneDx Holdings (WGS) reported Q1 2025 earnings on April 30, 2025 before market open.
What were GeneDx Holdings's Q1 2025 revenue and EPS?
GeneDx Holdings reported revenue of $87.1M and eps of $0.28 for Q1 2025.
Did GeneDx Holdings beat estimates in Q1 2025?
Revenue beat the consensus estimate of $85.3M by $1.8M. EPS beat the consensus estimate of $0.11 by $0.17.
How did GeneDx Holdings's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 39.6% from $62.4M a year earlier.
Where can I find GeneDx Holdings's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001818331-25-000070) and the 10-Q periodic report (0001818331-25-000071) directly on SEC EDGAR. The filing index links above go to sec.gov.